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ABSTRACT
Most hematopoietic malignancies are comprised of cells that are functionally heterogeneous, with only a subset
being responsible for tumor maintenance. These cancer stem cells are so named because they possess qualities
reminiscent of normal tissue stem cells including self-renewal, prolonged survival, and the ability to give rise to
cells with more differentiated characteristics. Effort is now focused on identifying cancer stem cells in various
hematopoietic malignancies, and defining the cells of origin such that the stepwise accumulation of genetic/epi-
genetic events necessary for cancer stem cell development can be delineated. A detailed understanding of these
processes could lead to development of therapeutics that more effectively treat hematopoietic malignancies and
potentially other cancers.
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Many adult tissues contain stem cells that are able
to divide and retain all of their proliferative and devel-
opmental potential (self-renewal), whereas at the same
time giving rise to all specialized cells necessary for
regeneration (differentiation). The most well-charac-
terized tissue-specific stem cells are hematopoietic
stem cells. Detailed characterization of hematopoietic
stem cells, committed hematopoietic progenitor cells,
and differentiated blood cells sets the stage for under-
standing hematopoietic malignancies [1], their cells of
origin, and the characteristics of cancer stem cells. In-
deed, the modern concept of human cancer stem cells
initiates from studies in acute myelogenous leukemias
(AMLs) [2].
The cancer stem cell concept is based on the idea
that tumors of a specific tissue often appear to ‘‘at-
tempt’’ to recapitulate the cellular heterogeneity found
in the tissues of origin, and thus there are cells in the
tumor that are stem cell-like giving rise to the varied
cell types. A fundamental test for this hypothesis is
whether tumor cells can be separated into those that
have the ability to regenerate the tumor, and those
that do not possess this ability. This cellular hierarchy
has been most clearly demonstrated in acute myeloge-
nous leukemias where some AMLs possess cells with
a unique immunophenotype that are able to initiate12leukemias in immunodeficient mice, whereas most
cells are unable to initiate leukemia development
[2,3]. Furthermore, the cells that initiate leukemias
also give rise to cells that have lost tumor-initiating ac-
tivity and thus recapitulate the cellular heterogeneity
found in the original tumor. Demonstrating this type
of functional hierarchy and cellular heterogeneity
identifies the presence of a leukemia (or cancer) stem
cell as they are presently defined.
CANCER STEM CELLS IN MYELOID MALIGNANCIES
The most detailed characterization of myeloid
cell development and stem cell biology has been per-
formed in murine systems, and has informed similar
approaches using human cells. Normal hematopoietic
stem cells contain self-renewal properties, which are
lost as the cells commit to myeloid development, giv-
ing rise to committed progenitor cells that, although
remaining multipotent, no longer possess long-term
self-renewal properties (Figure 1). Current studies
suggest that human HSC reside in a population of cells
that are CD341/CD382, and that CD341/CD381
cells contain populations that are committed to specific
myeloid fates. Initial studies that demonstrated the
presence of AML stem cells delineated the cell surface
immunophenotype as CD341/CD382, thus suggest-
ing similarities between normal and AML stem cells
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in many cases the AML stem cells also express antigens
such as CD123 (IL3-R) that are not normally found on
human HSC [4]. Also, experimental evidence suggests
that AML stem cells may respond differently to specific
small molecules (NFKB inhibitors and parthenolide),
providing evidence that there may be differences be-
tween normal and AML stem cells that can be lever-
aged for therapeutic benefit [5]. Detailed studies of
well-defined murine models of AML also demonstrate
phenotypic differences between normal and AML stem
cells, supporting the possibility that AML stem cells
have phenotypic, and hopefully functional differences
that can be manipulated to specifically target this pop-
ulation of cells. Studies in chronic myelogenous leuke-
mias (CML) have also been informative as to the
properties of human leukemia stem cells. It is widely
held that the cancer stem cell in chronic phase CML
Figure 1. Normal hematopoietic development and acute AML.
Normal hematopoietic development proceeds from hematopoietic
stem through fully differentiated blood cells. A number of cell fate
decisions are made during development that give rise to committed
hematopoietic progenitors such as common lymphoid progenitors
(CLP), common myeloid progenitors (CMP), granulocyte macro-
phage progenitors (GMP), and megakaryocyte erythroid progenitors
(MEP). The only normal cells with self-renewal potential are hema-
topoietic stem cells. Leukemia stem cells (LSC) arise from hemato-
poietic stem cells and potentially more committed progenitor cells,
and the fully developed AML cells are comprised of a mixture of cells
with a hierarchy somewhat similar to normal hematopoiesis.is similar if not identical to the normal HSC. However,
recent data suggest that the leukemia stem cell main-
taining blast crisis is more consistent with committed
hematopoietic progenitors [6]. Thus, it appears that
the characteristics of the leukemia stem cell evolve as
the leukemia transitions from chronic phase to blast
crisis. Future studies using improved model systems
and technologies will no doubt improve our under-
standing of the cellular heterogeneity of myeloid
malignancies and hopefully focus our attention on
the cells most important to eradicate in patients.
A related but distinct question is what cells are the
cell of origin for leukemias and leukemia stem cells. As
normal HSC possess indefinite self-renewal proper-
ties, and chronic phase CML is likely initiated from
HSC, it is clear that normal HSC can give rise to my-
eloid leukemias. However, the question arises as to
whether more committed myeloid cells can give rise
to AML (Figure 1). It would appear, based on the stud-
ies in blast crises CML, that leukemia stem cells can
possess an immunophenotype more consistent with
committed myeloid cells; however, these leukemias
likely progressed from an HSC that harbored the
BCR-ABL oncogene. Can AML be directly initiated
from a committed myeloid progenitor cell? Recent
studies in murine models have demonstrated that leu-
kemias can be initiated from common myeloid progen-
itors or granulocyte macrophage progenitors [7,8].
However, only certain fusion oncogenes such as those
involving the MLL gene on chromosome 11q23 pos-
sess this activity, whereas others such as BCR-ABL
do not possesses this ability [9]. The fact that leukemia
can be initiated from a cell that lacks intrinsic
self-renewal provides an opportunity to determine
the pathways responsible for these properties. Ongo-
ing studies will determine if AML can be initiated
from human myeloid progenitor cells, and most im-
portantly if leukemias initiated from different cells of
origin have different therapeutic outcomes.
CANCER STEM CELLS IN LYMPHOID MALIGNANCIES
Self-renewal capacity in most tissues is lost as cells
progress through their normal stages of differentia-
tion; for example, myeloid lineage blood cells beyond
the level of hematopoietic stem cells no longer possess
self-renewal capacity. A notable exception to differen-
tiation-associated loss of self-renewal is the lymphoid
system, where self-renewal capacity is preserved
through the memory lymphocyte stage to maintain
life-long immune memory [10,11]. Somatic hypermu-
tation serves as a marker for the stage of differentiation
at which B cell malignancies arise. In general, the pres-
ence of somatic hypermutation identifies a tumor as
having arisen in germinal center or postgerminal cen-
ter B cells, whereas the absence of mutation identifies
pregerminal center B cells. In contrast to myeloid
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cell malignancies (listed in bold italics) appear to arise at various stages of B cell differentiation: acute lymphocytic leukemia (ALL) from hema-
topoietic stem cells or pre-B cells, unfavorable chronic lymphocytic leukemia (CLL), and most mantle cell lymphomas (MCL) from the follicular
mantle B cells, most other non-Hodgkin lymphomas (NHL) from germinal center B cells, and multiple myeloma (MM), Hodgkin lymphoma
(HL), and favorable CLL from memory B cells.malignancies [2,3,12] but consonant with the lineage’s
preserved self-renewal capacity, immunoglobulin (Ig)
mutation patterns suggest that B cell malignancies
can arise from cells throughout the stages of B cell dif-
ferentiation (Figure 2).
Multiple myeloma (MM) has generally been con-
sidered a disease of malignant plasma cells, and indeed,many of clinical consequences of the disease result
from the plasma cell bulk. However, normal plasma
cells are terminally differentiated and lack self-renewal
capacity. Moreover, it has been clear for over 30 years
that only a minority of cells from mouse and human
MM were clonogenic [13,14]. Investigators called these
rare clonogenic cells ‘‘tumor stem cells’’ [13,14]. ThisFigure 3. Memory B cells as cancer stem cells. Although not ‘‘traditional’’ stem cells in that they lack multilineage potential, memory B cells can
be considered ‘‘honorary’’ stem cells—they are long-lived, self-renew, and differentiate into plasma cells to maintain long-term immune memory.
A transforming event in memory B cells may be able to produce MM, HL, or CLL, depending on the degree of differentiation associated with the
transforming event.
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proliferative capacity exclusively restricted to a small
subset of cancer cells, or alternatively all the cells
within a cancer retaining the capacity to proliferate
but only at a low rate. Insufficient tools available at
the time precluded investigators from distinguishing
which of these 2 possibilities explained the low clono-
genicity of MM. Cells phenotypically resembling ma-
ture B cells and sharing Ig gene sequences and idiotype
specificity with MM plasma cells have also been found
in the marrow and blood of patients with MM [15-17],
but their role in the pathogenesis of the disease has
been unclear. All these data suggest that MM might
originate from self-renewing B cells, rather than
plasma cells. In fact, it has recently been shown that
MM plasma cells actually arise from a small population
of self-renewing cancer stem cells that resemble mem-
ory B cells [18,19]. Not only do these clonotypic B cells
circulate in most patients but they also are resistant to
many standard anti-MM agents, and thus appear to be
responsible for most disease relapses.
Reed-Sternberg (RS) cells, the hallmark of Hodg-
kin lymphoma (HL), are the only blood cells other
than plasma cells to occasionally express CD138 [20].
This has led to the hypothesis that RS cells represent
aberrant plasma cell differentiation, supported by
data showing that RS cells from HL cell lines ex-
pressed a transcriptional profile similar to normal
and malignant plasma cells [21]. Thus, like plasma cells
in MM, RS may not represent HL stem cells. We and
others [22] found that HL cell lines include a small
population of cells that lack the RS markers CD15
and CD30 present on the rest of the cells, while ex-
pressing markers consistent with a memory B cell phe-
notype [23]. Moreover, this small subpopulation of
phenotypic memory B cells possessed all of the clono-
genic capacity within the HL cell lines. We also found
that most HL patients, including those with early-
stage disease, harbor circulating memory B cells with
the same clonal Ig gene rearrangement as the patients’
RS cells [23]. These data suggest that these clonotypic
memory B cells likely represent the HL stem cells. A
transforming event in hematopoietic stem cells can
produce several different malignancies, CML, myelo-
dysplastic syndrome (MDS), AML, and probably
even acute lymphocytic leuekemia, depending on the
degree differentiation associated with the oncogenic
hit. Similarly, a transforming event in memory B cells
may be able to produce either MM or HL (Figure 3).
CONCLUSION
Recent studies have begun to characterize the
functional heterogeneity of cells present in various tu-
mors. A discrete subpopulation that has properties
similar to normal tissue stem cells can be identified
in many hematologic malignancies. Future trials inhuman hematopoietic malignancies should be focused
on whether eradication of the so-called cancer stem
cells is critical to a successful therapeutic strategy. If
the clinical relevance of cancer stem cells is established,
targeting their unique properties should provide op-
portunities to develop novel therapeutics.
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